-+ 0.00%
-+ 0.00%
-+ 0.00%

MOLECULIN BIOTECH - MIRACLE TRIAL REPORTS 37% BLINDED CRC IN VENETOCLAX-FAILED R/R AML PATIENTS - SEC FILING

Reuters·07/31/2026 12:06:14

Please log in to view news